Showing results (411-420 of 1,271) with videos related to
Sort By:
Pageof 128
Psychopharmacology Bulletin|January 1, 1992
Disclosure of tardive dyskinesia: effect of written policy on risk disclosureN J Kennedy, J S SanbornPsychopharmacology Bulletin|October 21, 2003
Clinical management of perinatal depression: focus on paroxetineD Jeffrey Newport, Zachary N StowePsychopharmacology Bulletin|October 21, 2003
Paroxetine treatment of generalized anxiety disorderDavid V Sheehan, C Gloria MaoPsychopharmacology Bulletin|October 21, 2003
Paroxetine treatment of mood disorders in women: premenstrual dysphoric disorder and hot flashesKimberly A YonkersPsychopharmacology Bulletin|October 21, 2003
Incipient neurovulnerability and neuroprotection in early psychosisGregor E Berger, Stephen Wood, Patrick D McGorryPsychopharmacology Bulletin|October 21, 2003
Can serotonin and fluoxetine levels in plasma and platelets predict clinical response in depression?Paolo Castrogiovanni, Patrizia Blardi, Arianna De Lalla, et al.Psychopharmacology Bulletin|October 21, 2003
5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophreniaVicki L Ellingrod, Brian C Lund, Del Miller, et al.Psychopharmacology Bulletin|November 19, 2003
Pharmacology of valproateMichael J Owens, Charles B NemeroffPsychopharmacology Bulletin|January 1, 1992
Low dose oral haloperidol and blood levels in Alzheimer's disease: a preliminary studyD P Devanand, T Cooper, H A Sackeim, et al.Psychopharmacology Bulletin|January 1, 1992
Blocking the Ca(2+)-activated cytotoxic mechanisms of cholinergic neuronal death: a novel treatment strategy for Alzheimer's diseaseR J Branconnier, M E Branconnier, T M Walshe, et al.Pageof 128